Citigroup’s Beam Therapeutics BEAM Stock Holding History

Citigroup’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,000	Closed	-$510K	–	6088
2025 Q2	$510K	Buy	+30,000	New	+$522K	﹤0.01%	3613
2024 Q3	–	Sell	-25,000	Closed	-$586K	–	5682
2024 Q2	$586K	Sell	25,000 -24,900	-50%	-$612K	﹤0.01%	3286
2024 Q1	$1.65M	Buy	49,900 +25,000	+100%	+$779K	﹤0.01%	2593
2023 Q4	$678K	Buy	+24,900	New	+$619K	﹤0.01%	3168
2023 Q3	–	Sell	-17,500	Closed	-$559K	–	5669
2023 Q2	$559K	Hold	17,500	–	–	﹤0.01%	3299
2023 Q1	$536K	Buy	17,500 +1,600	+10%	+$63.1K	﹤0.01%	3084
2022 Q4	$622K	Buy	+15,900	New	+$712K	﹤0.01%	3007

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citigroup's BEAM Position: Q1 2026 in Review

Citigroup increased its Beam Therapeutics (BEAM) stake by 150% in Q1 2026, buying an estimated $1.11M and bringing the position to 66,858 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2815.

Citigroup first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $8.56M in Q1 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

Citigroup held 66,858 shares of Beam Therapeutics worth $1.59M as of Q1 2026.
Citigroup bought 40,101 Beam Therapeutics shares in Q1 2026, an estimated $1.11M.
Beam Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2815 holding.
Citigroup first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
Citigroup's Beam Therapeutics position peaked at $8.56M in Q1 2024.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.